Top sessions you should not miss at ISoP 2024, Montreal

The ISoP 2024 Montreal has something you definitely don’t want to miss! 

As we know, The International Society of Pharmacovigilance (ISoP) is an independent and non-profit society of professionals open to anyone who is keenly interested in the safe and effective use of medicinal products. This society achieves its aim “to foster science and learning in Pharmacovigilance in every country” by offering networking opportunities, a platform for exchanging ideas and information, affordable training and much more!

This year, ISoP is organizing its 23rd Annual Meeting from Oct 1-5, 2024, in Montreal to provide “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics”. Here’s a sneak peek into the must-attend sessions in the city of the Festivals: 

Session 1: Artificial Intelligence in Pharmacovigilance from the Industry Perspective

Date: Thursday, 3rd Oct, 2024

Time: 10:30 EDT

Location: CMR Theatre Symposia

Moderator: 

Felix Arellano, Roche, Spain. 

As the Global Head of Drug Safety at Roche, Felix oversees pharmacovigilance and patient safety activities across the entire Roche portfolio, spanning early development to established marketed products.

Keynote Speakers : 

Patrick Caubel from Pfizer, USA, will discuss the applications of Large Language Models (LLM) for case weighting and taxonomic data extraction in pharmacovigilance. 

Veronique Kugener from Takeda, USA, will share insights on the pros and cons of using Algorithms for causality assessments and predictive signal detection. 

Mariette Boerstoel from BMS, USA, will address the thought-provoking question- Gen AI in PV: Hallucination or Reality?

Session 4: RWE to identify, assess or monitor safety signals in digital era

Date: Thursday, 3rd Oct, 2024

Time: 13:30 EDT

Location: CMR Theatre Symposia

Moderator: 

Gianluca Trifiro, Verona University, Italy. In addition to being a Full Time Professor of Pharmacology at the University of Verona, he is a respected member of several organisations, including the Scientific Secretariat of the Pharmacovigilance Office of the Italian Drug Agency, a member of the Biosimilar Committee of the Sicilian Regional Department of Health. 

Keynote Speakers:

Darmendra Ramcharan, from GSK, USA, will address the question: Can AI improve RWEgeneration for safety signal management? 

Stefanie Spila-Alegiani/Marco Massari from the National Institute of Health, Italy, will share her experience on large-scale distributed database networks for postmarketing surveillance of drugs and vaccines. 

Luis Pinheiro from EMA, Netherlands, will discuss how RWE can support an informed regulatory decision-making process. He will also speak on The European Medicine Agency- promoted Darwin-EU project. 

Niklas Nore from UMC, Sweden, will recommend using RWE to inform decision-making throughout the pharmacovigilance signal management process. 

Session 5: Safety Challenges of New Generation Therapeutics

Date: Thursday, 3rd Oct, 2024

Time: 13:30 EDT

Location: CMR Cartier

Moderator: 

Jeremy Jokinen, BMS, USA. Jokinen is a senior leader at Bristol Myers Squibb (BMS) leader with experience in real-world evidence (RWE) and pharmacoepidemiology. At BMS, he focuses on integrating RWE into decision-making processes to enhance patient safety, evaluate drug effectiveness, and inform regulatory strategies. 

Keynote Speakers: 

Dr. Dirk Mentzer, MD, Paul-Ehrlich Institute, Germany, will address the challenges and specific aspects of pharmacovigilance of biomedicine and gene therapy. 

Kaori Nomura, Ph.D, MPH, from Teikyo Heisei University, Japan, will share insights on how Japan’s approach promotes evaluation and vigilance on cell and gene therapy products. 

Session 9: Digital Tools in Pharmacovigilance and how they can be improved

Date: Thursday, 3rd Oct, 2024

Time: 15:30 EDT

Location: CMR International 1

Moderator:

Mark Perrott, Axian, UK. Perrott is a renowned expert in the field of cell and gene therapy. At Axion, he is responsible for guiding innovative cell and gene therapies' safety strategies and compliance efforts. His expertise is precious in addressing the complex challenges in advanced therapy medicinal products (ATMPs). In this session, he will introduce the factors that drive the adoption of digital approaches in risk management. 

Keynote Speakers: 

Jean-Christophe Delumeau from the Institute of Pharmacovigilance, Canada, will discuss how ISoP is responding to digital risk management.

Lisa Rodriguez from BMS, USA, will present on the effectiveness of digital innovation in risk management, focusing on leveraging technology to mitigate and manage risks. 

Robert Massouh from GSK, UK, will highlight the challenges and opportunities in measuring the effectiveness of Risk Minimisation Measures. 

Priya Bahri from EMA, Netherlands, will offer insights on digital support to risk minimisation, providing a perspective on pharmacovigilance in a rapidly changing world.

This session also includes an Oral Presentation on - 

A Decision-Support Platform Powered by AI and Humans-in-the-Loop Boosts Efficiency and Assures Quality in FDA’s Pharmacovigilance.

Session 11: PV Training Needs and PV Professional Certification

Date: Friday, 4th Oct, 2024

Time: 10:30 EDT

Location: CMR Cartier 

Moderator: 

Jan Petracek CEO of iVigee, Czech Republic. Petracek has a proven track record of establishing, growing, and selling successful for-profit and non-profit organisations in pharmacovigilance. He has received multiple accolades, including the DIA Excellence in Service Award (2018) and the Queen's Award for International Trade (2019). iVigee specializes in providing innovative and sustainable solutions for drug safety and risk management. In this session, Jan will share key lessons learned from ISoP Global Pharmacovigilance Professional Certification.

Keynote Speakers: 

Nadja Jastrebova from UMC, Sweden, will address the current pharmacovigilance training needs among WHO PIDM members.

Ghita Benabdallah from Centre National de Pharmacovigilance, Morocco, will speak on involvement in Developing PV in LMIC through capacity building. 

Omar Aimer, the NASoP President, Canada, will present on Pharmacovigilance and Drug Safety training in Canada. 

This Session also includes an oral presentation on: 

Strengthening Signal Detection and Causality Assessment Capacity Among National Pharmacovigilance Centre Staff: A Stepwise Pedagogical Approach for UMC’s Hybrid Course. 

To ace your game, attend more such events. Stay Informed, Stay Connected —- Follow the events page on the Pharma Now Website for all the latest updates!